Cargando…
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial
BACKGROUND: The phase 3 VELIA trial evaluated veliparib with carboplatin/paclitaxel and as maintenance in patients with high-grade serous ovarian carcinoma. METHODS: Patients with previously untreated stage III–IV high-grade serous ovarian carcinoma were randomized 1:1:1 to control (placebo with car...
Autores principales: | Mizuno, Mika, Ito, Kimihiko, Nakai, Hidekatsu, Kato, Hidenori, Kamiura, Shoji, Ushijima, Kimio, Nagao, Shoji, Takano, Hirokuni, Okadome, Masao, Takekuma, Munetaka, Tokunaga, Hideki, Nagase, Satoru, Aoki, Daisuke, Coleman, Robert L., Nishimura, Yasuko, Ratajczak, Christine K., Hashiba, Hideyuki, Xiong, Hao, Katsumata, Noriyuki, Enomoto, Takayuki, Okamoto, Aikou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823063/ https://www.ncbi.nlm.nih.gov/pubmed/36534262 http://dx.doi.org/10.1007/s10147-022-02258-x |
Ejemplares similares
-
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial
por: Aghajanian, Carol, et al.
Publicado: (2022) -
Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
por: Nishio, Shin, et al.
Publicado: (2017) -
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study
por: You, Benoit, et al.
Publicado: (2023) -
Velia and the school of Salerno.
por: Nutton, V
Publicado: (1971) -
Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy
por: Abe, Masakazu, et al.
Publicado: (2015)